PCSA

Processa Pharmaceuticals, Inc. (PCSA) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Processa Pharmaceuticals, Inc. is a clinical-stage biotechnology company. As of the reporting date, the company had not yet recognized the financial impact of its acquisition of Vidya Therapeutics, Inc., which was consummated on July 28, 2026. The company operates as a single segment focused on advancing a clinical-stage Bruton's tyrosine kinase (BTK) inhibitor program and evaluating legacy pharmaceutical assets.

Key Financial Metrics

Other Notable Items:

• Digital Assets: The company holds Chiliz (CHZ) tokens valued at $472,003 as of June 30, 2026. This resulted in an unrealized loss of $828,172 and a realized loss of $159,005 during the six-month period.
• Debt: The company has no long-term debt. Current liabilities consist primarily of accounts payable ($1.66M) and accrued expenses ($0.73M).

Material Changes vs. Prior Period

• Liquidity Position: Cash and cash equivalents decreased significantly from $5.54 million at December 31, 2025, to $196,325 at June 30, 2026. This decline was driven by net cash used in operating activities of $5.6 million and investing activities of $0.3 million (net purchase of digital assets).
• Operating Expenses: Research and development (R&D) expenses decreased by approximately $1.58 million year-over-year (six months) to $2.46 million, primarily due to a reduction in preclinical and clinical trial costs as the NGC-Cap Phase 2 trial was placed on hold. General and administrative (G&A) expenses increased by $0.45 million to $3.21 million, driven by higher professional fees, insurance, and franchise taxes.
• Equity Status: The company moved from positive stockholders' equity of $5.58 million at year-end 2025 to a deficit of $0.32 million at June 30, 2026, due to the accumulated net loss.

Outlook, Management Commentary, and Subsequent Events

Subsequent Events (Post-June 30, 2026):

• Vidya Acquisition: On July 28, 2026, Processa acquired Vidya Therapeutics, Inc., adding the lead asset VT-7208 (a BTK inhibitor) to its pipeline. Concurrently, the company closed a private placement financing raising $200 million in gross proceeds ($183.3 million net).
• Liquidity Resolution: Management stated that prior to the financing, net assets were insufficient to fund future operations. However, following the $183.3 million net proceeds received in late July 2026, management believes liquid assets are sufficient to meet obligations for at least one year.
• Elion Settlement: On July 23, 2026, the company terminated its license agreement with Elion Oncology, Inc., returning the PCS6422 program to Elion. Processa agreed to pay $650,000 in legal fees and grant Elion a 7.5% equity interest in any future spin-out entity involving specific legacy assets. The ongoing Phase 2 trial for PCS6422 is being closed.

Risks and Contingencies:

• Going Concern: While the subsequent financing alleviates immediate liquidity concerns, the company has a history of losses and no product revenue. Future funding remains necessary.
• Stockholder Approval: The Vidya Acquisition and the issuance of Series A Preferred Stock require stockholder approval for conversion to common stock. Failure to obtain approval could force a cash settlement of the preferred shares.
• Legal Proceedings: The company is defending against a lawsuit filed by former investors alleging fraud and negligent misrepresentation regarding a 2021 private offering. A motion to dismiss is pending.

Investor Verification Checklist

• Financing Closure: Verify the final closing details and net proceeds of the $200 million private placement associated with the Vidya acquisition.
• Stockholder Vote: Monitor the status of the stockholder meeting required to approve the conversion of Series A Preferred Stock into common stock.
• VT-7208 Timeline: Confirm the projected timelines for Phase 2 proof-of-concept data in food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS).
• Elion Settlement Impact: Assess the financial impact of the $650,000 settlement payment and the potential dilution from the 7.5% equity grant to Elion in a future spin-out.
• Digital Asset Exposure: Review the company's continued strategy regarding the holding and trading of Chiliz (CHZ) tokens, which contributed significantly to the Q2 2026 net loss.